Reducing vascular events risk in patients with dyslipidaemia: An update for clinicians

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 5, 2011, Pages 307-323

  Hermans, Michel P ^a   Fruchart, Jean Charles ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Fondation Caur et Artares   (France)

Author keywords

apolipoprotein B; atherogenic dyslipidaemia; cardiovascular risk; diabetes; low density lipoprotein cholesterol; metabolic syndrome

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CELL FUNCTION; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; EXERCISE; HEALTH CARE QUALITY; HEALTH EDUCATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLEIOTROPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 81355132295     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311413952     Document Type: Review

References (115)

1. ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., Leiter, L.A. et al. (2010 a) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.
2. ACCORD Study Group; ACCORD Eye Study Group, Chew, E.Y., Ambrosius, W.T., Davis, M.D., Danis, R.P., Gangaputra, S., Greven, C.M. et al. (2010 b) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363; 233–244.
3. Adiels M. Olofsson S.-O. Taskinen M.-R. Borén J. (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 1225–1236.
4. Ahmad J. Khan A.R. Ahmed F. Siddiqui S. (2007) Non-HDL cholesterol versus apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia. Diab Metab Syndr 1: 29–36.
5. Alberti K.G. Eckel R.H. Grundy S.M. Zimmet P.Z. Cleeman J.I. Donato K.A. et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645.
6. American Diabetes Association (2010) Clinical practice recommendations. Diabetes Care 33: S1–S100.
7. Assmann G. Cullen P. Fruchart J.C. Greten H. Naruszewicz M. Olsson A. et al. (2005) Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis 15: 373–381.
8. Assmann G. Cullen P. Schulte H. (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 105: 310–315.
9. Assmann G. Schulte H. Cullen P. Seedorf U. (2007) Assessing risk of myocardial infarction and stroke: New data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest 37: 925–932.
10. Assmann G. Schulte H. Seedorf U. (2008) Cardiovascular risk assessment in the metabolic syndrome: Results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond) 32(Suppl 2): S11–S16.
11. Ballantyne C.M. Bertolami M. Hernandez Garcia H.R. Nul D. Stein E.A. Theroux P. et al. (2006) Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 151(975): e1–e9.
12. Ballantyne C.M. Raichlen J.S. Cain V.A. (2008) Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 52: 626–632.
13. Barter P. Gotto A.M. LaRosa J.C. Maroni J. Szarek M. Grundy S.M. et al. (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301–1310.
14. Bittner V. Johnson B.D. Zineh I. Rogers W.J. Vido D. Marroquin O.C. et al. (2009) The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 157: 548–555.
15. ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R., Leiter, L.A. et al. (2010 a) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362.
16. Blasiole D.A. Davis R.A. Attie A.D. (2007) The physiological and molecular regulation of lipoprotein assembly and secretion. Mol Biosyst 3: 608–619.
17. Bonetti P.O. Lerman L.O. Napoli C. Lerman A. (2003) Statin effects beyond lipid lowering–are they clinically relevant? Eur Heart J 24: 225–248.
18. Bonora E. Targher G. Formentini G. Calcaterra F. Lombardi S. Marini F. et al. (2004) The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects Prospective data from the Verona Diabetes Complications Study. Diabet Med 21: 52–58.
19. Brites F.D. Bonavita C.D. de Geitere C. Cloës M. Delfly B. Yael M.J. et al. (2000) Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 152: 181–192.
20. Brown G. Albers J.J. Fisher L.D. Schaefer S.M. Lin J.T. Kaplan C. et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298.
21. Bruno G. Merletti F. Biggeri A. Bargero G. Ferrero S. Runzo C. et al. (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: The Casale Monferrato Study. Diabetes Care 27: 2689–2694.
22. Brunzell J.D. Davidson M. Furberg C.D. Goldberg R.B. Howard B.V. Stein J.H. et al. (2008) Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512–1524.
23. Buyken A.E. von Eckardstein A. Schulte H. Cullen P. Assmann G. (2007) Type 2 diabetes mellitus and risk of coronary heart disease: Results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil 14: 230–236.
24. Carey V.J. Bishop L. Laranjo N. Harschfield B.J. Kwiat C. Sacks F.M. (2010) Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 106: 757–763.
25. Chapman M.J. Redfern J.S. McGovern M.E. Giral P. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 126: 314–345.
26. Coleman R.L. Stevens R.J. Retnakaran R. Holman R.R. (2007) Framingham, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30: 1292–1293.
27. Colhoun H.M. Betteridge D.J. Durrington P.N. Hitman G.A. Neil H.A. Livingstone S.J. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364: 685–696.
28. Cordero A. Andrés E. Ordoñez B. León M. Laclaustra M. Grima A. et al. (2009) Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol 104: 1393–1397.
29. Cordero A. Laclaustra M. León M. Casasnovas J.A. Grima A. Luengo E. et al. (2008) Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol 102: 424–428.
30. Costet P. (2010) Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther 126: 263–278.
31. da Luz P.L. Favarato D. Faria-Neto J.R. Lemos P. Chagas A.C. (2008) High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 63: 427–432.
32. Damani S.B. Topol E.J. (2007) Future use of genomics in coronary artery disease. J Am Coll Cardiol 50: 1933–1940.
33. Davidson M.H. (2005) Reducing residual risk for patients on statin therapy: The potential role of combination therapy. Am J Cardiol 96: 3K–13K.
34. Davignon J. Cohn J.S. (1996) Triglycerides: A risk factor for coronary heart disease. Atherosclerosis 124(Suppl): S57–S64.
35. deGoma E.M. Leeper N.J. Heidenreich P.A. (2008) Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 51: 49–55.
36. deGoma E.M. Rader D.J. (2011) Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 8: 266–277.
37. Dehout F. Haumont S. Gaham N. Amoussou-Guenou K.D. Hermans M.P. (2008) Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: Prevalence, gender differences and HOMA-hyperbolic product. Diab Metab Syndr 2: 5–11.
38. Denke M.A. (2005) Weighing in before the fight Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus Apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112: 3368–3370.
39. Dobiásová M. Frohlich J. (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 34: 583–588.
40. Ducobu J. Scheen A. van Gaal L. Velkeniers B. Hermans M. (2008) Belgian Expert opinion: How to reduce the residual risk in atherogenic dyslipidemic patients: Place of fibrates. Acta Cardiol 63: 235–248.
41. Eichler K. Puhan M.A. Steurer J. Bachmann L.M. (2007) Prediction of first coronary events with the Framingham score: A systematic review. Am Heart J 153: 722–731.
42. Fioretto P. Dodson P.M. Ziegler D. Rosenson R.S. (2010) Residual microvascular risk in diabetes: Unmet needs and future directions. Nat Rev Endocrinol 6: 19–25.
43. Forrester J.S. (2010) Redefining normal low-density lipoprotein cholesterol: A strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol 56: 630–636.
44. Friedewald V.E. Ballantyne C.M. Davidson M.H. Guyton J.R. Roberts W.C. (2008) The editor's roundtable: Lipid management beyond statins – reducing residual cardiovascular risk. Am J Cardiol 102: 559–567.
45. Fruchart J.C. (2009) Peroxisome proliferator-activated receptor-α (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205: 1–8.
46. Fruchart J.C. (2010) PCSK9: The functional relevance of fenofibrate-statin combination therapy to reduce residual cardiovascular risk. Int J Diab Mellitus 30 December [Epub ahead of Print].
47. Fruchart J.C. Duriez P. (2002) HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 13: 605–616.
48. Fruchart J.C. Nierman M.C. Stroes E.S. Kastelein J.J. Duriez P. (2004) New risk factors for atherosclerosis and patient risk assessment. Circulation 109(23 Suppl 1): III15–III19.
49. Fruchart J.-C. Sacks F.M. Hermans M.P. (2010) Implications of the ACCORD lipid study: Perspective from the Residual Risk Reduction Initiative (R3i). Curr Med Res Opin 26: 1793–1797.
50. Fruchart J.-C. Sacks F. Hermans M.P. Assmann G. Brown V. Ceska R. et al. (2008a) Executive statement: The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients A condensed position paper by the Residual Risk Reduction Initiative (R3i). Diab Vasc Dis Res 5: 319–335.
51. Fruchart J.-C. Sacks F. Hermans M.P. Assmann G. Brown W.V. Ceska R. et al. (2008b) The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102(Suppl): 1–34.
52. Gaede P. Lund-Andersen H. Parving H.H. Pedersen O. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580–591.
53. Gaede P. Vedel P. Larsen N. Jensen G.V. Parving H.H. Pedersen O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393.
54. Genest J. McPherson R. Frohlich J. Anderson T. Campbell N. Carpentier A. et al. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 25: 567–579.
55. Graham I. Atar D. Borch-Johnsen K. Boysen G. Burell G. Cifkova R. et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice Executive summary. Eur Heart J 28: 2375–2414.
56. Grundy S.M. Cleeman J.I. Daniels S.R. Donato K.A. Eckel R.H. Franklin B.A. et al. (2005) Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752.
57. Grundy S.M. Cleeman J.I. Merz C.N. Brewer H.B. Clark L.T. Hunninghake D.B. et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.
58. Haffner S.M. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234.
59. Hanak V. Munoz J. Teague J. Stanley A. Jr Bittner V. (2004) Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol 94: 219–222.
60. Hermans M.P. (2007) Diabetic macro- and microvascular disease in type 2 diabetes. Diab Vasc Dis Res 4: S7–S11.
61. Hermans M.P. (2010) Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: Subgroup analysis from FIELD. Curr Cardiol Rev 6: 112–118.
62. Hermans M.P. Ahn S.A. Amoussou-Guenou K.D. Rousseau M.F. (2010a) Impact of metabolic syndrome on microvascular complications in type 2 diabetes. Diab Metab Syndr 4: 150–154.
63. Hermans M.P. Ahn S.A. Rousseau M.F. (2007) The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. Diab Metab Syndr 1: 23–28.
64. Hermans M.P. Ahn S.A. Rousseau M.F. (2009a) Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea syndrome. Diab Metab Syndr 3: 50–54.
65. Hermans M.P. Ahn S.A. Rousseau M.F. (2009b) Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes. Diabetes Metab 35: 484–489.
66. Hermans M.P. Ahn S.A. Rousseau M.F. (2010b) log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 9: 88–89.
67. Hermans M.P. Castro Cabezas M. Strandberg T. Ferrieres J. Feely J. Elisaff M. et al. (2010c) Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): Overall findings from eight countries. Curr Med Res Opin 26: 445–454.
68. Hermans M.P. Fruchart J.C. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidaemia: Where do we go from here. Clinical Lipidology 5: 811–826.
69. Hermans M.P. Muls E. Michel G. Elisaf M. Brotons C. Matthys A. (2010d) Optimal type 2 diabetes management including benchmarking and standard treatment Baseline European results. Atherosclerosis Suppl 11: 44–45.
70. Hermans M.P. Sacks F.M. Ahn S.A. Rousseau M.F. (2011) Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant ratio and unbiased equivalence. Cardiovasc Diabetol 10: 20–21.
71. HPS Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361: 2005–2016.
72. Jones P.H. (2008) Expert perspective: Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 102: 41L–47L.
73. Jun M. Foote C. Lv J. Neal B. Patel A. Nicholls S.J. et al. (2010) Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet 375: 1875–1884.
74. Juutilainen A. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. (2005) Type 2 diabetes as a ‘coronary heart disease equivalent’ An 18-year prospective population-based study in Finnish subjects. Diabetes Care 28: 2901–2907.
75. Kannel W.B. Vasan R.S. Keyes M.J. Sullivan L.M. Robins S.J. (2008) Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 101: 497–501.
76. Katcher H.I. Hill A.M. Lanford J.L. Yoo J.S. Kris-Etherton P.M. (2009) Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am 38: 45–78.
77. Kathiresan S. Otvos J.D. Sullivan L.M. Keyes M.J. Schaefer E.J. Wilson P.W. et al. (2006) Increased small low-density lipoprotein particle number A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113: 20–29.
78. Kim-Dorner S.J. Deuster P.A. Zeno S.A. Remaley A.T. Poth M. (2010) Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism 59: 299–304.
79. Kothari V. Stevens R.J. Adler A.I. Stratton I.M. Manley S.E. Neil H.A. et al. (2002) UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33: 1776–1781.
80. LaRosa J.C. Grundy S.M. Waters D.D. Shear C. Barter P. Fruchart J.C. et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
81. Libby P.L. (2005) The forgotten majority Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46: 1225–1228.
82. Lu W. Resnick H.E. Jablonski K.A. Jones K.L. Jain A.K. Howard W.J. et al. (2003) Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care 26: 16–23.
83. Manninen V. Tenkanen L. Koskinen P. Huttunen J.K. Mänttäri M. Heinonen O.P. et al. (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study Implications for treatment. Circulation 85: 37–45.
84. Mazzone T. Chait A. Plutzky J. (2008) Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 371: 1800–1809.
85. Mendivil C.O. Zheng C. Furtado J. Lel J. Sacks F.M. (2010) Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 30: 239–245.
86. Metascreen Writing Committee (2006) The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes Results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 29: 2701–2707.
87. Millán Núñez-Cortés J. Montoya J.P. Salas X.P. Hernández Mijares A. Carey V.J. Hermans M.P. et al. (2011) The REALIST (REsiduAl risk, Lipids and Standard Therapies) study: An analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinol Nutr 58: 38–47.
88. Nicholls S.J. Gordon A. Johansson J. Wolski K. Ballantyne C.M. Kastelein J.J. et al. (2011) Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 57: 1111–1119.
89. Pischon T. Girman G.J. Sacks F.M. Rifai N. Stampfer N.J. Rimm E.B. (2005) Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112: 3375–3383.
90. Polonsky T.S. Davidson M.H. (2008) Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy with combination therapy. Am J Cardiol 101: 27B–35B.
91. Ridker P.M. Danielson E. Fonseca F.A. Genest J. Gotto A.M. Kastelein J.J. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
92. Rosenson R.S. (2009) Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207: 328–335.
93. Rosenson R.S. Davidson M.H. Pourfarzib R. (2010) Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 213: 1–7.
94. Sacks F.M. Carey V.J. Fruchart J.C. (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363: 692–694.
95. Sacks F.M. Tonkin A.M. Shepherd J. Braunwald E. Cobbe S. Hawkins C.M. Keech A. et al. (2000) Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 102: 1893–1900.
96. Sadikot S. Hermans M.P. (2010) Here we go again … The metabolic syndrome revisited!. Diab Metab Syndr 4: 111–120.
97. Sadikot S.M. Misra A. (2007) The metabolic syndrome: an exercise in utility or futility? Diab Metab Syndr 1: 3–21.
98. Schramm T.K. Gislason G.H. Køber L. Rasmussen S. Rasmussen J.N. Abildstrøm S.Z. et al. (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 117: 1945–1954.
99. Shepherd J. Barter P. Carmena R. Deedwania P. Fruchart J.C. Haffner S. et al. (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 29: 1220–1226.
100. Sniderman A.D. (2005) Apolipoprotein B versus non-high-density lipoprotein cholesterol And the winner is. Circulation 112: 3366–3367.
101. Sniderman A. Williams K. Cobbaert C. (2009) ApoB versus non-HDL-C: What to do when they disagree. Curr Atheroscler Rep 11: 358–363.
102. Staels B. Dallongeville J. Auwerx J. Schoonjans K. Leitersdorf E. Fruchart J.C. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088–2093.
103. Stevens R.J. Coleman R.L. Adler A.I. Stratton I.M. Matthews D.R. Holman R.R. (2004) UKPDS 66: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 27: 201–207.
104. Stevens R.J. Kothari V. Adler A.I. Stratton I.M. United Kingdom Prospective Diabetes Study (UKPDS) Group (2001) The UKPDS Risk Engine: A model for the risk of coronary heart disease in type 2 diabetes. Clin Science 101: 671–679.
105. Stratton I.M. Cull C.A. Adler A.I. Matthews D.R. Neil H.A. Holman R.R. (2006) Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 49: 1761–1769.
106. Sulkes D. Brown B.G. Krauss R.M. Segrest J.P. Sniderman A.D. Roberts W.C. (2008) The editor's roundtable: Expanded versus standard lipid panels in assessing and managing cardiovascular risk. Am J Cardiol 101: 828–842.
107. Sumner A.E. Vega G.L. Genovese D.J. Finley K.B. Bergman R.N. Boston R.C. (2005) Normal triglyceride levels despite insulin resistance in African Americans: Role of lipoprotein lipase. Metabolism 54: 902–909.
108. Volek J.S. Fernandez M.L. Feinman R.D. Phinney S.D. (2008) Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 47: 307–318.
109. Waksman R. Torguson R. Kent K.M. Pichard A.D. Suddath W.O. Satler L.F. et al. (2010) A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55: 2727–2735.
110. Walldius G. Jungner I. (2006) The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 259: 493–519.
111. Walldius G. Jungner I. Holme I. Aastveit A.H. Kolar W. Steiner E. (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 358: 2026–2033.
112. Watts G.F. Ooi E.M.M. Chan D.C. (2009) Therapeutic regulation of apoB100 metabolism in insulin resistance in-vivo. Pharmacol Ther 123: 281–291.
113. Wilson P.W. (2009) Risk scores for prediction of coronary heart disease: An update. Endocrinol Metab Clin North Am 38: 33–44.
114. Yusuf S. Hawken S. Ôunpuu S. Dans T. Avezum A. Lanas F. et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 364: 937–952.
115. Zheng C. Khoo C. Furtado J. Sacks F.M. (2010) Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121: 1722–1734.